Graciela Racaro Joins Signant Health as COO

Signant Health has announced the appointment of Graciela Racaro as chief operating officer (COO).

Racaro will leverage her clinical operations and regulatory expertise to drive operational efficiency at scale and enhanced the customer experience.

Graciela Racaro said:

“This is an exciting time to join Signant.

“As clinical development evolves towards greater globalisation and digitalisation, Signant is ideally positioned with the solutions, operational infrastructure, and scientific support needed to deliver successful trials in today’s complex research landscape.

“I look forward to ensuring our customers’ success and guiding Signant toward achieving its strategic goals.”

Racaro joins the company following an 18-year tenure with global clinical research organisation (CRO), Parexel.

Most recently, she served as executive vice president of clinical development and operational head of the company’s biotech division, where she led multidisciplinary teams.

Roger Smith, Signant’s chief executive officer, said:

“Graciela’s deep expertise in drug development, commercialisation, and operational leadership align with Signant’s trajectory to become the clinical trial technology partner the industry seeks for scaled, global delivery grounded in science and service.

“Her record of success in accelerating timelines, reducing burdens and barriers, and expertly navigating the global regulatory environment led us to the conclusion that she is the change-driving leader needed to head our delivery organisation through our next phase of growth.

“We are excited to have her on board.”